For instance, long-acting amylin analogues are being developed to manage obesity effectively. These analogues, such as cagrilintide, have shown promising results in reducing body weight in both ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Existing GLP-1 receptor agonist therapies like semaglutide or the peptide Amylin analogue Pramlintide have limited impact due to high costs, accessibility, and undesirable side effects.

Novo Nordisk’s Combination Amylin Analog and GLP-1 Agonist Combo While Novo Nordisk is experiencing drama sales growth, with Ozempic and Wegovy reaching 69% year-over-year (YoY) revenue growth ...

The advent of GLP-1 treatments has been a game changer in the medical sector for weight loss and chronic obesity. The GLP-1 market is currently dominated by semaglutide (Ozempic and Wegovy ...